{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:47:38Z","timestamp":1790480858143,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,4,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy of pretargeted radioimmunotherapy (pRAIT) with bispecific monoclonal antibody (BsMAb) and a iodine-131 (<jats:sup>131<\/jats:sup>I) \u2013labeled bivalent hapten is evaluated. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Twenty-nine patients with advanced, progressive MTC, as documented by short serum calcitonin doubling times (Ct DTs), received an anti\u2013carcinoembryonic antigen (CEA)\/anti\u2013diethylenetriamine pentaacetic acid (DTPA) \u2013indium BsMAb, followed 4 days later by a <jats:sup>131<\/jats:sup>I-labeled bivalent hapten. Overall survival (OS) was compared with 39 contemporaneous untreated MTC patients with comparable prognostic indicators. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> OS was significantly longer in high-risk, treated patients (Ct DT &lt; 2 years) than in high-risk, untreated patients (median OS, 110 v 61 months; P &lt; .030). Forty-seven percent of patients, defined as biologic responders by a more than 100% increase in CtDT, experienced significantly longer survival than nonresponders (median OS, 159 v 109 months; P &lt; .035) and untreated patients (median OS, 159 v 61 months; P &lt; .010). Treated patients with bone\/bone-marrow disease had a longer survival than patients without such involvement (10-year OS, 83% v 14%; P &lt; .023). Toxicity was mainly hematologic and related to bone\/bone-marrow tumor spread. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> pRAIT against CEA induced long-term disease stabilization and a significantly longer survival in high-risk patients with Ct DTs less than 2 years, compared with similarly high-risk, untreated patients. Ct DT and bone-marrow involvement appear to be prognostic indicators in MTC patients who undergo pRAIT. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.4917","type":"journal-article","created":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T01:44:41Z","timestamp":1142905481000},"page":"1705-1711","source":"Crossref","is-referenced-by-count":203,"title":["Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti\u2013Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group"],"prefix":"10.1200","volume":"24","author":[{"given":"Jean-Fran\u00e7ois","family":"Chatal","sequence":"first","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Campion","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Bardet","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Vuillez","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Charbonnel","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rohmer","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsing","family":"Chang","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Sharkey","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Barbet","sequence":"additional","affiliation":[{"name":"From the Department of Nuclear Medicine, Institut R\u00e9gional du Cancer; Department of Endocrinology, University Hospital; Inserm U601, Universit\u00e9 de Nantes, Nantes; Department of Nuclear Medicine, Centre Fran\u00e7ois Baclesse, Caen; Department of Nuclear Medicine, University Hospital, Grenoble; Department of Endocrinology, University Hospital, Angers, France; IBC Pharmaceuticals Inc; Immunomedics Inc, Morris Plains; and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199010000-00002"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-5-889"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0044"},{"key":"R4","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Bardet S, Hoefnagel CA, et al: Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I\/II clinical trial. Clin Cancer Res 5:3190s,1999-3198s,"},{"key":"R5","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Faivre-Chauvet A, Ferrer L, et al: Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargetring of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9:3973s,2003-3981s,"},{"key":"R6","unstructured":"Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al: Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled-DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 34:1662,1993-1671,"},{"key":"R7","unstructured":"Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM: HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 16:294,1993-299,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601843"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.4051"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.18.622"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1500"},{"key":"R13","unstructured":"Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46:115s,2005-125s,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403751"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.73"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881101)62:9<1899::AID-CNCR2820620905>3.0.CO;2-C"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.4917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:17:50Z","timestamp":1653513470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.4917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,20]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,4,20]]}},"alternative-id":["10.1200\/JCO.2005.04.4917"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.4917","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,20]]}}}